1
. Identification of therapeutic targets and development of effective target therapies are crucial and highly demanding. The well tolerated Bruton's tyrosine Kinase (BTK) inhibitor, ibrutinib (formally called PCI-32765) 2 , represents one of the most exciting breakthroughs in the field of B cell malignancy therapy.
In clinical investigation ibrutinib has been shown to have significant clinical activity against B cell malignancies including CLL and it was recently approved for the treatment of mantle cell lymphoma and CLL 3, 4 . BTK is a critical component of the B cell receptor (BCR) signaling pathway 5 . Beside BTK, other kinases such as IL2-inducible T-cell kinase (ITK) have been identified as targets of ibrutinib 6 . To confirm that genetic ablation of functional BTK recapitulated long-term BTK inhibition by ibrutinib, Woyach and the colleagues treated the Eµ-TCL1 mice with ibrutinib or vehicle starting at 1 month of age and found that ibrutinib treated mice showed a significantly delayed leukemia onset and extended overall survival compared to control mice.
These data were strikingly similar to genetic inactivation of BTK shown in XID/TCL1 mice. The authors also demonstrated that Eµ-TCL1 leukemic cell transplanted SCID mice treated with ibrutinib had inhibited BCR signaling and survived longer than vehicle treated mice, lending confidence to the notion that ibrutinib was having a direct inhibitory effect on the CLL cells themselves.
Interestingly 
